Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer.

Abstract excerpt

Lymphangioleiomyomatosis (LAM) is a rare cystic, destructive lung disease occurring almost exclusively in females. Bi-allelic inactivating tuberous sclerosis complex (TSC) gene mutations occur in LAM cells, resulting in activation of the mTORC1 pathway. Pivotal clinical trials have demonstrated that inhibition of mTORC1 with sirolimus can induce a partial response of TSC-associated tumours and decrease the rate...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biopsy
• Share to Genetic Testing
• Share to Molecular Targeted Therapy